近日,德琪医药发布公告称,公司与优时比(UCB)就用于自身免疫性疾病的CD19/CD3双特异性T细胞连接器ATG-201达成全球独家授权协议。根据授权协议,德琪医药的全资附属公司AntengeneBiologicsLimited及德琪(杭州)生物有限公司将授予优时比进一步开发、生产及商业化ATG-201的全球独家授权。德琪医药将获得8000万美元的首付款及近期里程碑付款,其中包括6000万美元的...
Source Link近日,德琪医药发布公告称,公司与优时比(UCB)就用于自身免疫性疾病的CD19/CD3双特异性T细胞连接器ATG-201达成全球独家授权协议。根据授权协议,德琪医药的全资附属公司AntengeneBiologicsLimited及德琪(杭州)生物有限公司将授予优时比进一步开发、生产及商业化ATG-201的全球独家授权。德琪医药将获得8000万美元的首付款及近期里程碑付款,其中包括6000万美元的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.